LLY ▲ +0.2% - Eli Lilly and Company $LLY Eli Lilly: Foundayo Shows Greater Weight Loss and A1C Reduction vs. Oral Semaglutide 25 mg in Indirect Comparison ? • At 52 weeks, Foundayo 17.2 mg was associated with 1.5% greater weight loss and 0.3% greater A1C reduction. • Analysis used data from ACHIEVE-3 and PIONEER PLUS rather than a direct head-to-head trial at those doses. • In ACHIEVE-3, Foundayo 17.2 mg reduced A1C by 2.2% and body weight by 9.2% vs. 1.4% and 5.3% with oral semaglutide 14 mg. 29-SEP-2026 05:34 AM ET